Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Characteristics of a real world cohort of Canadians treated with benralizumab

Stephen G Noorduyn, Mackenzie A Hamilton, Brett Lancaster, Alain Gendron, Lawrence Mbuagbaw, Erika Penz
European Respiratory Journal 2021 58: PA3726; DOI: 10.1183/13993003.congress-2021.PA3726
Stephen G Noorduyn
1AstraZeneca Canada, Mississauga, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: SNoorduyn@gmail.com
Mackenzie A Hamilton
2University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brett Lancaster
1AstraZeneca Canada, Mississauga, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Gendron
3University of Montreal, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Mbuagbaw
4McMaster University, Hamilton, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Penz
5University of Saskatchewan, Saskatoon, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Nearly 8% of patients with asthma in Canada have severe disease (Asthma Canada, 2014). Phenotyping may be required to determine dominant profile prior to treatment with a biologic therapy. Benralizumab is an anti-IL-5Rα biologic used as add-on maintenance therapy for severe eosinophilic asthma.

Objective: To describe the characteristics of patients initiating benralizumab for severe eosinophilic asthma in the real world setting.

Methods: This is an early analysis of the POWER study (NCT03833141), part of the XALOC multi-country study program. Eligible patients were recruited from 23 clinics in Canada if they had blood eosinophils ≥300c/µL, total Asthma Control Questionnaire (ACQ-6) score ≥1.5, and were benralizumab naïve. Baseline data include patient sociodemographic data and self-reported asthma control, disease severity, and quality of life (QoL).

Results: As of Jan 2021, 78 of 200 individuals had completed a baseline assessment. Mean (standard deviation; SD) age at entry was 55(16) years and 72% were female. At baseline 28% of patients report active OCS use.

The baseline mean(SD) ACQ-6 score was 3.18(0.98). Most patients rated their asthma severity as moderate and reported a median (interquartile range) of 3 (2-4) exacerbations in the prior year. Mean (SD) utility and global health rating on the EQ-5D-5L visual analogue scale were 0.61(0.34) and 56.88(20.12) respectively.

Conclusions: At baseline, patients view their asthma as moderate severity but demonstrate poor control, frequent exacerbations, and meet clinical criteria for severe disease. Patients showed disease-related impairment and overall lower QoL at baseline relative to the average Canadian utility score of 0.86 (Guertin, 2018).

  • Treatments
  • Severe asthma
  • Asthma - management

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3726.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Characteristics of a real world cohort of Canadians treated with benralizumab
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Characteristics of a real world cohort of Canadians treated with benralizumab
Stephen G Noorduyn, Mackenzie A Hamilton, Brett Lancaster, Alain Gendron, Lawrence Mbuagbaw, Erika Penz
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3726; DOI: 10.1183/13993003.congress-2021.PA3726

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Characteristics of a real world cohort of Canadians treated with benralizumab
Stephen G Noorduyn, Mackenzie A Hamilton, Brett Lancaster, Alain Gendron, Lawrence Mbuagbaw, Erika Penz
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3726; DOI: 10.1183/13993003.congress-2021.PA3726
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
  • RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
  • Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society